Trevi Therapeutics, Inc. (TRVI) stock
Close on Nov 12, 2026Market cap $1.94BP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026
Valuation
- Market cap
- $1.94B
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 6.41
- Dividend yield
- –
- Free cash flow yield
- -3.18%
Fundamentals
- Net income
- -$60.76M
- EPS, diluted
- -$0.39
- Free cash flow
- -$61.69M
- Book value per share
- $1.90
- Diluted shares
- 160M
Trading
- Next earnings
- Mar 16, 2027 (estimated, during market hours)
- Previous close
- $14.81
- Open
- $14.51
- Day's range
- $13.11 – $14.60
- Volume
- 2,014,851
- Average volume (20 days)
- 1,702,979
- Index membership
- Russell 2000 (since Jun 2023), Russell 3000 (since Aug 2023)
- Beta (5 years)
- 0.89
- 52-week range
- $9.82 – $20.22
- RSI (14 days)
- 58.7
- Volatility (1 year)
- 58.8%
- Relative volume
- 0.74×
- WACC
- 9.3%
On 1 of our idea list: Institutions accumulating
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2019, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | TRVI | S&P 500 | Difference | TRVI per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +5.3% | -2.7% | +8.0 pts | ||
| 3 months | -23.2% | -1.7% | −21.4 pts | ||
| Year to date | +8.8% | +11.9% | −3.1 pts | ||
| 1 year | +14.9% | +12.0% | +3.0 pts | ||
| 3 years | +939.7% | +78.2% | +861.5 pts | +118.3% | +21.2% |
| 5 years | +1094.7% | +73.2% | +1021.5 pts | +64.2% | +11.6% |
Nine years at a glance
Fiscal years 2017 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Trevi Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Results
About Trevi Therapeutics
Pharmaceutical Preparations
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops therapies for serious respiratory conditions. Its primary product candidate is Haduvio, an oral extended-release formulation of nalbuphine that targets opioid receptors in the central and peripheral nervous systems to inhibit the cough reflex. The company focuses its drug development activities on treating chronic cough in individuals diagnosed with idiopathic pulmonary fibrosis, non-IPF interstitial lung disease, and refractory chronic cough. Its prospective patient base consists of individuals suffering from severe, persistent coughing associated with these chronic pulmonary disorders.
Company profile, executives and historyTrevi Therapeutics stock: common questions
What is Trevi Therapeutics's stock price?
TRVI closed at $13.62 on Nov 12, 2026, down 8.07% on the day. Over the past 52 weeks it traded between $9.82 and $20.22.
What is Trevi Therapeutics's market cap?
Trevi Therapeutics was worth $1.94B at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is TRVI's P/E ratio?
Trevi Therapeutics lost money over the twelve months to Sep 30, 2026 (diluted EPS -$0.39), so it has no meaningful P/E ratio.
Does Trevi Therapeutics pay a dividend?
No. Trevi Therapeutics has not paid a cash dividend over the last twelve months.
When does Trevi Therapeutics report earnings next?
Trevi Therapeutics is expected to report Q4 FY2026 results on Mar 16, 2027, during market hours. The date is estimated from its past reporting pattern until the company confirms it.
How has TRVI stock performed over the past year?
Including dividends, TRVI returned +14.9% over the past year, against +12.0% for the S&P 500.
How many TRVI shares are sold short?
17M shares were sold short at the latest FINRA report, 13.51% of the float, or 10.1 days of average trading volume.
Who are Trevi Therapeutics's competitors?
Companies most similar to Trevi Therapeutics by business, industry and size include TENX, GRI, GOSS, GYRE, DWTX.
See a number that looks wrong?